Research Article: Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
Abstract:
Background: Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). However, the efficacy and safety of pralsetinib in real world has rarely been reported.
No summary available.